Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 337

1.

Authorized generic drugs, price competition, and consumers' welfare.

Berndt ER, Mortimer R, Bhattacharjya A, Parece A, Tuttle E.

Health Aff (Millwood). 2007 May-Jun;26(3):790-9. Review.

PMID:
17485758
[PubMed - indexed for MEDLINE]
Free Article
2.

Generic script share and the price of brand-name drugs: the role of consumer choice.

Rizzo JA, Zeckhauser R.

Int J Health Care Finance Econ. 2009 Sep;9(3):291-316. doi: 10.1007/s10754-008-9052-0. Epub 2009 Jan 8.

PMID:
19130220
[PubMed - indexed for MEDLINE]
3.

The effect of generic competition on the price of brand-name drugs.

Lexchin J.

Health Policy. 2004 Apr;68(1):47-54.

PMID:
15033552
[PubMed - indexed for MEDLINE]
4.

Competition between brand-name and generics--analysis on pricing of brand-name pharmaceutical.

Kong Y.

Health Econ. 2009 May;18(5):591-606. doi: 10.1002/hec.1392.

PMID:
18816580
[PubMed - indexed for MEDLINE]
5.

Price and welfare effects of a pharmaceutical substitution reform.

Granlund D.

J Health Econ. 2010 Dec;29(6):856-65. doi: 10.1016/j.jhealeco.2010.08.003. Epub 2010 Aug 19.

PMID:
20832130
[PubMed - indexed for MEDLINE]
6.

Effect of generic drug competition on the price of prescription drugs in Ontario.

Lexchin J.

CMAJ. 1993 Jan 1;148(1):35-8.

PMID:
8439888
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

High prices for generics in Australia - more competition might help.

Bulfone L.

Aust Health Rev. 2009 May;33(2):200-14.

PMID:
19563309
[PubMed - indexed for MEDLINE]
8.

The strategic response by pharmaceutical firms to the Medicaid most-favored-customer rules.

Scott Morton F.

Rand J Econ. 1997 Summer;28(2):269-90.

PMID:
11794358
[PubMed - indexed for MEDLINE]
9.

Follow-on biologics: competition in the biopharmaceutical marketplace.

Devine JW, Cline RR, Farley JF.

J Am Pharm Assoc (2003). 2006 Mar-Apr;46(2):193-201; quiz 202-4. Review.

PMID:
16602229
[PubMed - indexed for MEDLINE]
10.

Some drugs more equal than others: pseudo-generics and commercial practice.

Probyn AJ.

Aust Health Rev. 2004 Nov 8;28(2):207-17.

PMID:
15527401
[PubMed - indexed for MEDLINE]
11.

Sword or shield? An overview and competitive analysis of the marketing of "authorized generics".

Zain S.

Food Drug Law J. 2007;62(4):739-77. No abstract available.

PMID:
18557229
[PubMed - indexed for MEDLINE]
12.

Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.

Mansfield SJ.

Aust Health Rev. 2014 Feb;38(1):6-15. doi: 10.1071/AH12009.

PMID:
24480618
[PubMed - indexed for MEDLINE]
13.

Delayed access to generic medicine: a comment on the Hatch-Waxman Act and the "approval bottleneck".

Patel AN.

Fordham Law Rev. 2009 Nov;78(2):1075-115.

PMID:
19938382
[PubMed - indexed for MEDLINE]
14.

[Intention of purchasing generic prescription drugs on the part of consumers in Asturias, Spain].

González Hernando S, González Mieres C, Díaz Martín AM.

Rev Esp Salud Publica. 2003 Nov-Dec;77(6):691-9. Spanish.

PMID:
14965061
[PubMed - indexed for MEDLINE]
15.

What's in a name? Use of brand versus generic drug names in United States outpatient practice.

Steinman MA, Chren MM, Landefeld CS.

J Gen Intern Med. 2007 May;22(5):645-8.

PMID:
17443372
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

[Price differences between generic and innovator medicines in Brazil].

Vieira FS, Zucchi P.

Rev Saude Publica. 2006 Jun;40(3):444-9. Epub 2006 Jun 23. Portuguese.

PMID:
16810368
[PubMed - indexed for MEDLINE]
Free Article
17.

Why drug prices will go lower.

Tully S.

Fortune. 1993 May 3;127(9):56-8, 60, 62 passim.

PMID:
10125261
[PubMed - indexed for MEDLINE]
18.

[Availability of generic drugs in the public sector and prices in the private sector in different regions of Brazil].

Miranda ES, Pinto Cdu B, dos Reis AL, Emmerick IC, Campos MR, Luiza VL, Osorio-de-Castro CG.

Cad Saude Publica. 2009 Oct;25(10):2147-58. Portuguese.

PMID:
19851615
[PubMed - indexed for MEDLINE]
Free Article
19.

Dynamic competition in pharmaceuticals. Patent expiry, generic penetration, and industry structure.

Magazzini L, Pammolli F, Riccaboni M.

Eur J Health Econ. 2004 Jun;5(2):175-82.

PMID:
15452754
[PubMed - indexed for MEDLINE]
20.

Product-line extensions and pricing strategies of brand-name drugs facing patent expiration.

Hong SH, Shepherd MD, Scoones D, Wan TT.

J Manag Care Pharm. 2005 Nov-Dec;11(9):746-54.

PMID:
16300418
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk